Psychiatric drugs. Excited by glutamate.
Holden
Constance
C
D000818:Animals; D001008:Anxiety Disorders / Q000188:drug therapy; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D001927:Brain Diseases / Q000188:drug therapy* / Q000503:physiopathology; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy; D004298:Dopamine / Q000378:metabolism; D018683:Excitatory Amino Acid Agents / Q000627:therapeutic use*; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D018698:Glutamic Acid / Q000502:physiology*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000503:physiopathology; D009474:Neurons / Q000502:physiology; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology; D017470:Receptors, Glutamate / Q000187:drug effects* / Q000378:metabolism; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology; D019966:Substance-Related Disorders / Q000188:drug therapy / Q000503:physiopathology; D009435:Synaptic Transmission / Q000187:drug effects
D001643:Bridged Bicyclo Compounds; D018683:Excitatory Amino Acid Agents; D018691:Excitatory Amino Acid Antagonists; D017470:Receptors, Glutamate; D018094:Receptors, Metabotropic Glutamate; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; C104753:eglumetad; D004298:Dopamine